SFS
FBRX icon

Sowell Financial Services’s Forte Biosciences FBRX Stock Holding History

Sowell Financial Services’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1
Closed -$1K – 1232
2021
Q1 		$1K Buy
+1
New +$819 ﹤0.01% 2932

Other funds holding FBRX

FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Sowell Financial Services's FBRX Position: Q2 2021 in Review

Sowell Financial Services sold out of Forte Biosciences (FBRX) in Q2 2021, closing a stake of 1 share — an estimated $1K sold.

Sowell Financial Services first reported a position in FBRX in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 75 funds tracked by Wall St. Rank hold FBRX as of Q2 2021.

  • Sowell Financial Services reported no remaining Forte Biosciences position as of Q2 2021 after selling out during the quarter.
  • Sowell Financial Services sold 1 Forte Biosciences share in Q2 2021, an estimated $1K.
  • Sowell Financial Services first reported a position in Forte Biosciences in Q1 2021 and held it in 1 quarter.
  • Sowell Financial Services's Forte Biosciences position peaked at $1K in Q1 2021.
  • 75 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2021.

Based on Sowell Financial Services's 13F filing for Q2 2021, filed 5 Aug 2021.